Quick jump to page content
Main Navigation
Main Content
Sidebar
Register
Login
Toggle navigation
Home
About
About the Journal
Submissions
Editorial Team
Privacy Statement
Contact
Current
Archives
Submission
Search
Search
Search articles for
Advanced filters
Published After
2017
2018
2019
2020
2021
2022
2023
January
February
March
April
May
June
July
August
September
October
November
December
01
02
03
04
05
06
07
08
09
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
Published Before
2017
2018
2019
2020
2021
2022
2023
January
February
March
April
May
June
July
August
September
October
November
December
01
02
03
04
05
06
07
08
09
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
By Author
Search Results
Bimekizumab versus secukinumab continuous maintenance of response at every visit through one year in patients with moderate to severe plaque psoriasis: Post-hoc results from the BE RADIANT phase 3b trial
RB Warren, C Conrad, P Foley, L Iversen, RG Langley, G Kokolakis, L Davis, V Vanvoorden, S Wiegratz, JF Merola
Page s70
Poster PDF
Bimekizumab versus secukinumab efficacy across subgroups of patients with moderate to severe plaque psoriasis: Results from the multicenter, randomized, double-blinded phase 3b BE RADIANT trial
Andrew Blauvelt, Lars Iversen, Sandy McBride, Melinda Gooderham, Petra Staubach, Paul Yamauchi, Fabienne Staelens, Veerle Vanoorden, Katy White, Paolo Gisondi
Page s53
Poster PDF
Bimekizumab efficacy and safety through two years in patients with moderate psoriasis: Analysis of pooled data from five phase 3/3b clinical trials
Andrew Blauvelt, Linda Stein Gold, Melinda Gooderham, Bruce Strober, Andreas Pinter, Jose-Manuel Carrascosa, Paolo Gisondi, Jonathan Bleier, Cynthia Madden, Delphine Deherder, Natalie Nunez Gomez, Richard B Warren
Page s67
Poster PDF
Maintenance of bimekizumab efficacy through 2 years in patients with moderate to severe plaque psoriasis: Pooled results from five phase 3/3b trials
D Thaçi, A Armstrong, M Lebwohl, A Blauvelt, C Paul, L Puig, M Wang, V Vanvoorden, C Madden, S Wiegratz, D Deherder, KB Gordon
Page s71
Poster PDF
Mean percent PASI improvement with bimekizumab in patients with moderate to severe plaque psoriasis: Pooled results from four phase 3/3b trials
Andrew Blauvelt, George Han, Steve Tyring, Jennifer Soung, Tae Oh, Leah Davis, Veerle Vanoorden, Mark Lebwohl
Page s55
Poster PDF
Bimekizumab Efficacy and Safety versus Adalimumab in Patients with Moderate to Severe Plaque Psoriasis: Results from a Multicenter, Randomized, Double-Blinded Active Comparator-Controlled Phase 3 Trial (BE SURE)
RB Warren, A Blauvelt, J Bagel, KA Papp, P Yamauchi, A Armstrong, R Langley, V Vanvoorden, D De Cuyper, L Peterson, N Cross, K Reich
Page s15
Poster PDF
Bimekizumab versus Ustekinumab Efficacy Across Subgroups of Patients with Moderate to Severe Plaque Psoriasis: Results from the Multicenter, Randomized, Double-Blinded Phase 3 BE VIVID Trial
B Strober, JG Krueger, N Magnolo, R Vender, DP Toth, D Thaci, M Wang, C Cioffi, C Madden, RB Warren
Page s16
Poster PDF
Bimekizumab Versus Ustekinumab in Plaque Psoriasis: Lasting Efficacy Translates to Rapid and Sustained Improvements in Quality of Life in the BE VIVID Multicenter, Randomized, Double-Blinded Phase 3 Trial
K Gordon, P Foley, P Rich, K Duffin, A Pinter, CEM Griffiths, M Wang, V Vanvoorden, F Staelens, V Ciaravino, JF Merola
Page s17
Poster PDF
1 - 8 of 8 items
×
Modal Header
